Peripheral NeuropathiesArchives
Inhibition of S100A4 decreases neurotoxic astrocyte reactivity and attenuates neuropathic pain via the TLR4/NF-κB pathway in a rat model of spinal nerve ligation
Peripheral Neuropathies 10 min.
Neuropathic pain (NP) occurs due to lesions or diseases affecting the somatosensory system [1]. It is difficult to diagnose because of its heterogeneity [2, 3]. Treatment is also challenging because of the limited number of effective drugs and significant side effects. Investigating the aetiology and...
Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation
Peripheral Neuropathies 4 min.
Myasthenia gravis (MG) is an acquired autoimmune disease of the neuromuscular junction characterized by muscle weakness that is intensified by repeated exercise. The disease initially manifests as usual ocular symptoms, such as ptosis and diplopia, whereas limb, bulbar, and respiratory muscle weakness...
A case of retinal ciliary artery obstruction complicated after nonarteritic anterior ischemic optic neuropathy
Peripheral Neuropathies 2 min.
The etiology of NAION is attributed to infarction of the Optic Nerve Head (ONH), which was primarily supplied by the posterior ciliary arteries. The majority of NAION cases caused by transient non-perfusion or hypoperfusion of the ONH circulation [1]. The CrAO, a vascular variant, also originated from...
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data
Peripheral Neuropathies 6 min.
Myasthenia Gravis (MG) is a rare, heterogeneous neuromuscular junction (NMJ) disorder, characterized by muscle weakness and fatigability. It is an autoimmune disease driven by antibodies targeting components of the post-synaptic endplate at the NMJ [1, 2]. The majority of antibodies are directed against...
Fucoidan reduces NET accumulation and alleviates chemotherapy-induced peripheral neuropathy via the gut–blood–DRG axis
Peripheral Neuropathies 8 min.
Current treatment modalities for cancer include surgical interventions, radiotherapy, and chemotherapy drug regimens, although they are often accompanied by severe adverse effects. These drugs frequently elicit sensory receptor stimulation and damage, precipitating CIPN and profoundly impacting treatment...
Qualitative Evaluation of the Influence of Acute Oxaliplatin‐Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life
Peripheral Neuropathies 5 min.
For an increasing number of patients, cancer becomes a chronic disease. While healing or prolonging life is the primary goal for patients with cancer during the curative phase, quality of life (QoL) becomes more important in an advanced or chronic stage. Together with the advances in treatment, the length...
Update on therapy of chronic immune-mediated neuropathies
Peripheral Neuropathies 6 min.
Chronic inflammatory neuropathies are a heterogeneous group of disorders deemed to be caused by an autoimmune reaction against peripheral nerves. They mainly include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and its variants, neuropathy associated with IgM monoclonal gammopathy...
